Anorexia-cachexia syndrome - Pharmacological management

Hospital Pharmacist

Volumn 14, Issue 8, 2007, Pages 257-263

  Andrew, Inga ^a   Hawkins, Colette ^a   Waterfield, Kerry ^a   Kirkpatrick, Graeme ^a  

^a UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYDAMINE; CANNABINOID; CHLORHEXIDINE; CORTICOSTEROID; CYPROHEPTADINE; DEXAMETHASONE; DOMPERIDONE; DRONABINOL; EICOSAPENTANOIC ACID; FLUCONAZOLE; GESTAGEN; HYDROCORTISONE; IBUPROFEN; MEGESTROL ACETATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PILOCARPINE; POLYUNSATURATED FATTY ACID; PREDNISOLONE; SALIVA SUBSTITUTE; THALIDOMIDE; UNCLASSIFIED DRUG; ZINC SULFATE;

ABDOMINAL DISCOMFORT; ABNORMAL BODY SMELL; ADRENAL SUPPRESSION; ALOPECIA; ANOREXIA; BELCHING; BREAKTHROUGH BLEEDING; CACHEXIA; CHEWING GUM; CLINICAL TRIAL; CONFUSION; CUSHINGOID SYMPTOM; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DYSPEPSIA; EDEMA; EUPHORIA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FLATULENCE; FLUSHING; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MOUTH PAIN; NAUSEA; NAUSEA AND VOMITING; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PHARMACIST; RASH; RESTLESSNESS; REVIEW; SATIETY; SIDE EFFECT; SOMNOLENCE; SWEATING; TASTE DISORDER; THROMBOEMBOLISM; THRUSH; URINARY FREQUENCY; WEIGHT REDUCTION; XEROSTOMIA;

EID: 36148934896     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:135-41.
2. Della Cuna GR. Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. European Journal of Cancer and Clinical Oncology 1989;25:1817-21.
3. Lopez AP, Roque Figuls M, Cuchi GU, Berenstein EG, Pasies BA, Alegre MB et al. Systematic review of megestrol acetate in the treatment of anorexia cachexia syndrome. Journal of Pain and Symptom Management 2004;27:360-68.
4. McCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalmic neuropeptide Y concentrations. European Journal of Pharmacology 1994;265: 99-102.
5. Rowland KM. Randomised double blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive stage small-cell lung cancer:a North Central Cancer Treatment group study. Journal of Clinical oncology 1996;14:135-41.
6. McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS. A prospective randomised study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. British Journal of Cancer 1999;79:495-500.
7. Bruera E, Neumann CM, Pituskin E, Calder K, Ball G, Hanson J. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Annals of Oncology 1999;10:857-9.
8. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005;54:540-45.
9. Barber MD, Fearon KC, Tisdale MJ, McMillan DC, Ross JA. Effect of a fish oil enriched nutritional supplement on metabolic medicators in patients with pancreatic cancer cachexia. Nutrition and Cancer 2001;40:118-24.
10. Fearon KCH. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003;52:1479-86.
11. Fox PC, Atkinson JC, Macynski AA, Wolff A, King DS, Valdez IH et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia) Archives of Internal Medicine 1991;151:1149-52.
12. Davies AN. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. Palliative Medicine 2000;14:197-203.
13. Visch LL, Gravenmade EJ, Schaub RM, Van Putten WL, Vissink A. A double-blind crossover trial of CMC- and mucin-containing saliva substitutes. International Journal of Oral and Maxillofacial Surgery 1986;15:395-400.
14. Furumoto EK, Barker GJ, Carter-Hanson C, Barker B. Subjective and clinical evaluation of oral lubricants in xerostomic patients. Special Care in Dentistry 1998;18:113-18.
15. Lissoni P, Paolorossi F, Tancini G, Barni S, Ardizzoia A, Brivio F et al. Is there a role for melatonin in the treatment of neoplastic cachexia? European Journal of Cancer 1996;32:1340-43.
16. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with drobinol. Pharmacology Biochemistry and Behaviour 1991;40:695-700.
17. Regelson W, Butler JR, Schulz J, Kirk T, Peek L, Green ML et al. Tetrahydrocannabinol as an effective antidepressant and appetite stimulating agent in advanced cancer patients. In: Braude MC, Szara S (editors) The pharmacology of marijuana: A monograph of the National Institute of Drug Abuse. New York:Raven;1976.
18. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Milliard JA et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer treatment group Study. Journal of Clinical Oncology 2002;20:567-73.
19. Kardinal CG. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657-62.
20. Argiles J, Almendro V, Busquets S, Lopez-Soriano FJ. The pharmacological treatment of cachexia. Current Drug Targets 2004;5:265-77.